What TRB Chemedica International . does

TRB Chemedica International SA is a privately-held, family-owned Swiss pharmaceutical company founded in 1980 by Dr. Guido Di Napoli and headquartered in Geneva (Carouge), Switzerland. The company develops, manufactures, and distributes pharmaceutical and medical device products across three core therapeutic areas: musculoskeletal disorders (primarily osteoarthritis and tendinopathy), ophthalmology (dry eye disease and ocular surgery), and neurology (neurodegenerative conditions including Parkinson's disease and stroke). Its technology platform centres on three proprietary capabilities: pharmaceutical-grade sodium hyaluronate produced via a non-animal biofermentation process (commercialised since 1998 with the OSTENIL launch), GM1 ganglioside extraction and purification from nerve cell membranes (manufactured since the early 1990s), and diacerein formulation as an oral interleukin-1 inhibitor for osteoarthritis.

TRB operates a vertically integrated business model with three GMP-qualified manufacturing sites in Vouvry (Switzerland, Swissmedic-authorised), Buenos Aires (Argentina, ANMAT/MERCOSUR/COFEPRIS compliant), and São Paulo (Brazil). Products reach over 70 countries through a combination of wholly-owned subsidiaries in Europe, Asia-Pacific, the Americas, and the Middle East & Africa, complemented by qualified distribution partners. The company employs more than 1,100 people globally and reports no publicly disclosed revenue. Key product families include OSTENIL (intra-articular hyaluronic acid viscosupplementation), VISMED and Hylovis (sodium hyaluronate-based ophthalmic solutions including preservative-free multi-dose variants), Visiol (ophthalmic viscosurgical device for cataract surgery), Artrodar (diacerein tablets for osteoarthritis), Remogen Omega (omega-3-containing eye drops), and GM1 ganglioside formulations for neurological applications. The company is led by President Alessandro Di Napoli, who assumed leadership in 2019, continuing the founding family's stewardship.

Name

TRB Chemedica International .

Legal name

TRB Chemedica International SA

Website

https://trbchemedica.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

501–1,000 employees

Short description

TRB Chemedica International is a Swiss, family-owned specialty pharmaceutical company that develops and manufactures hyaluronic acid-based, diacerein, and GM1 ganglioside products for musculoskeletal, ophthalmology, and neurology indications, distributing them in 70+ countries through subsidiaries and partners.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Ophthalmic Goods (3851)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Viscosupplementation injections
• Ophthalmic lubricants
• Osteoarthritis treatments
• Neurological therapeutics
• Sodium hyaluronate products

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical products sales: Sale of proprietary pharmaceutical products including viscosupplementation injections (Ostenil line), ophthalmic solutions (Vismed line), diacerein tablets (Artrodar), and neurological products (GM1 ganglioside). Products are sold through subsidiaries and distribution partners in 70+ countries.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

TRB Chemedica International manufactures and markets pharmaceutical products for musculoskeletal disorders, ophthalmology, and neurology. Its portfolio is built on proprietary hyaluronic acid (sodium hyaluronate) technology, diacerein formulations, and GM1 ganglioside, sold under brands such as OSTENIL (intra-articular injections for osteoarthritis), VISMED and Hylovis (lubricant eye drops for dry eye disease), Visiol (ophthalmic viscosurgical devices), Artrodar (oral osteoarthritis therapy), and GM1 ganglioside for neurological conditions. The company distributes these pharmaceutical products through wholly-owned subsidiaries and distribution partners in 70+ countries.

Product overview

TRB Chemedica International develops and manufactures pharmaceutical products across three core therapeutic areas: Musculoskeletal Disorders (including osteoarthritis and tendinopathy), Ophthalmology (dry eye disease and ocular surgery), and Neurology (GM1 ganglioside for neurodegenerative conditions). The company's product portfolio centers on hyaluronic acid-based formulations (sodium hyaluronate), diacerein, and GM1 ganglioside. Key product families include: VISMED® line of preservative-free sodium hyaluronate eye drops (including gel and multi-dose variants) for dry eye disease; Ostenil® family of intra-articular hyaluronic acid injections for osteoarthritis and tendinopathy; Hylovis® hyaluronic acid ophthalmic formulations; Visiol® ophthalmic viscosurgical device; Artrodar® diacerein for osteoarthritis; and Remogen® Omega (omega-3 fatty acid-containing eye drops). All products are manufactured under stringent quality standards with GMP compliance.

Differentiator

Problem solved

Functional benefit

Brands

• VISMED: Sodium hyaluronate-based lubricant eye drop brand for dry eye disease, including VISMED, VISMED Gel, VISMED Light, VISMED Multi, and VISMED Gel Multi product variants.
• OSTENIL
• Artrodar
• Hylovis
• Relys
• Vislube
• Remogen
• Viscoseal
• Visiol
• Hialsorb-Cold
• Droptonic
• Idroflog
• Tendoactive
• Silsteo
• HaxlOne

Products and services

• Ostenil Intra-articular hyaluronic acid injection for viscosupplementation in osteoarthritis; the first fermentation-derived HA product approved for all synovial joints. For orthopaedic surgeons and rheumatologists treating osteoarthritis.
• Ostenil Plus Enhanced intra-articular hyaluronic acid formulation for osteoarthritis treatment, building on the Ostenil platform. For orthopaedic surgeons managing osteoarthritis symptoms.
• Ostenil Mini Lower-concentration intra-articular hyaluronic acid injection for osteoarthritis, providing an alternative dosing option within the Ostenil product family.
• Ostenil Tendon Hyaluronic acid injection specifically formulated for tendinopathy treatment, extending the Ostenil platform into tendon care. For sports medicine physicians and orthopaedic specialists.
• Vismed Sodium hyaluronate-based lubricant eye drops providing hydration, protection, and stabilization of the ocular surface for patients with dry eye disease. For ophthalmologists and patients.
• Vismed Gel Gel formulation of sodium hyaluronate eye drops offering enhanced viscosity for more severe dry eye symptoms.
• Vismed Multi Multi-dose formulation of sodium hyaluronate eye drops without preservatives, providing ocular surface hydration with convenient dosing.
• Hylovis Hyaluronic acid-based ophthalmic solution for eye comfort and hydration, part of the company's ophthalmology product portfolio.
• Hylovis Multi Multi-dose hyaluronic acid ophthalmic formulation for eye comfort and hydration.
• Hylovis Lipo Liposomal hyaluronic acid formulation designed for enhanced ocular hydration.
• Remogen Hyaluronic acid-based eye drops for dry eye disease treatment within the Remogen brand family.
• Remogen Omega First lubricant eye drops containing omega-3 fatty acids, designed to treat dry eye disease.
• Artrodar Diacerein-based oral medication for long-term treatment of knee and hip osteoarthritis, acting by inhibiting interleukin-1 and targeting inflammatory processes.
• Visiol Ophthalmic viscosurgical device (OVD) containing hyaluronic acid and mannitol for use during cataract and intraocular surgery, providing tissue protection and reducing oxidative stress. For ophthalmic surgeons.
• Viscoseal Synovial fluid substitute based on hyaluronic acid for post-arthroscopy joint care. For orthopaedic surgeons performing arthroscopy procedures.
• GM1 Ganglioside Naturally occurring ganglioside for neurological applications including stroke, spinal cord injury, Parkinson's disease, and Alzheimer's disease, with neuroprotective and neurotrophic properties. For neurologists.
• Tendoactive Hyaluronic acid-based product for tendon health and tendinopathy management.
• Droptonic Eye drop product for ocular surface conditions.

Quantifiable outcome

• Trusted by patients and doctors in over 70 countries
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Academic and research institutionscoreStrategic or Co-development PartnerTRB collaborates with academic and industry partners for early research including target and disease biology, molecule selection, lead optimisation, preclinical evaluation, and early formulation feasibility. Ongoing collaboration across the organisation helps translate scientific work into practical real-world solutions.

Scale indicators6 records

Recent moves14 records

Expansion highlights5 records

Broad incumbents

• Alcon: Global leader in eye care and cataract/IOL surgery, with viscosurgical devices and ocular surface products that compete with TRB's Visiol OVD and VISMED franchise.
• Bausch + Lomb: Major global ophthalmology and eye care company with products spanning dry eye, cataract surgery, and contact lens solutions, overlapping with TRB's ophthalmology and ocular surgery portfolio at a much larger scale.
• AbbVie (Allergan Aesthetics): Large diversified pharma with a major ophthalmology portfolio (including Restasis for dry eye and surgical/eye care brands via Allergan), competing in adjacent segments to TRB's ophthalmology franchise at global scale.
• Chiesi Farmaceutici: European privately-owned specialty pharma comparable in scale, family-controlled structure, and multi-country commercial footprint, competing in overlapping specialty care and hospital channels though not in HA per se.

Direct peers

• Seikagaku Corporation: Japanese specialty pharma with a hyaluronic acid platform spanning joint injection (Supartz) and ophthalmology, overlapping closely with TRB's musculoskeletal and ophthalmology product lines.
• Anika Therapeutics: US-based specialty company focused on hyaluronic acid viscosupplementation (Monovisc, Orthovisc) and regenerative medicine, competing head-to-head with TRB's OSTENIL franchise in the OA joint care segment.
• Santen Pharmaceutical: Japanese ophthalmology specialist with prescription dry eye and ocular surgery products, a direct global peer to TRB's ophthalmology franchise including VISMED and Visiol.
• Fidia Farmaceutici: Italian specialty pharma and a pioneer in hyaluronic acid-based intra-articular and topical products (e.g., Hyalgan), directly competing with TRB's OSTENIL viscosupplementation line in osteoarthritis and related musculoskeletal indications globally.
• Bioventus: Global orthobiologics player selling viscosupplementation brands such as Durolane and Gel-One, directly competing with TRB's intra-articular HA portfolio in osteoarthritis and broader musculoskeletal care.
• URSAPHARM Arzneimittel GmbH: German specialty pharma focused on ophthalmology and hyaluronic acid-based eye drops (e.g., Hylo-Comod), competing directly with TRB's VISMED and Hylovis lines in dry eye and ocular surface care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TRB_Intl
• YouTubeyoutube.com/channel/UCfIX5hLnjBC2lNgGeysJMrg
• LinkedInbr.linkedin.com/company/trb-chemedica-international-sa

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TRB Chemedica International .